The incidence of shingles increases with age, but it is also a factor of immune competence. When I treated HIV patients, it was often one of the intial presenting symptoms in an otherwise healthy young individual. Immunity and the immune system is a complex issue, and having had exposure to HZV zoster does not provide prevention of a future recurrence, so it is the reason they recommend vaccination. The risk/incidence vs. cost are a factor in determining the age at which it is recommend. But there are recommendations for other vaccines much earlier such as HPV vaccine. In contrast, exposure to multiple proteins from a virus that may be bound to cells or fragments is more likely to result in autoimmunity and viruses are constantly mutating and finding ways to evade the immune system. The design and delivery of the vaccine, is an evolving science. In this case they seem to have achieved a very high efficacy, how this compares to individuals that have already had COVID remains to be seen. I agree that there is very little information on COVID reinfection, but there are documented cases. In HIV neither the immune system, nor any vaccines to date has been effective in minimizing the development/progression of infection. There is no simple answer.
In medicine there is nothing that is absolute, as I like to say just shades of grey. Ironically there are many treatments that have been approved, that years later the efficacy came into doubt, or long term ramifications were found. Between the Pfizer and Moderna vaccine, there is no clear superior candidate that I see from an efficacy point of view and the current data available, I prefer the latter because I do some consulting for them and feel their science is sound. The same (mRNA) vaccine has been used and is being developed for a numerous other indications, so this is not the first occurence of this technology.